<DOC>
	<DOCNO>NCT02597036</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug know LY3127804 give monotherapy combination Ramucirumab participant advance metastatic solid tumor . The study also include safety exploration combination LY3127804 plus ramucirumab paclitaxel</brief_summary>
	<brief_title>A Study LY3127804 With Ramucirumab Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have diagnosis cancer advance and/or metastatic . Have disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Have adequate organ function . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Have discontinue previous treatment cancer least 28 day 5 halflives prior study enrolment . Have serious preexist medical condition . Have receive treatment drug predominantly target Ang2 activity . Have symptomatic central nervous system ( CNS ) malignancy metastasis . Have current hematologic malignancy . Have active fungal , bacterial , and/or know viral infection . Have correct QT interval use Fridericia 's correction ( QTcF ) &gt; 470 msec screen electrocardiogram ( ECG ) several consecutive day assessment . Have know sensitivity mAbs therapeutic protein . Have history hypertensive crisis hypertensive encephalopathy current poorly control hypertension despite standard medical management . Have significant bleeding disorder vasculitis Grade ≥3 bleed episode within 3 month prior receive treatment . Receive anticoagulation therapy therapeutic dose . Have experience arterial venothrombotic thromboembolic event within 6 month prior study treatment . Have liver cirrhosis ChildPugh class B bad cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis . The participant pregnant prior randomization breastfeeding . The participant sensory peripheral neuropathy ≥ Grade 2 ( Part E ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced , Angiopoietin</keyword>
</DOC>